Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis.
Abidi S, Achar J, Assao Neino MM, Bang D, Benedetti A, Brode S, Campbell JR, Casas EC, Conradie F, Dravniece G, du Cros P, Falzon D, Jaramillo E, Kuaban C, Lan Z, Lange C, Li PZ, Makhmudova M, Maug AKJ, Menzies D, Migliori GB, Miller A, Myrzaliev B, Ndjeka N, Noeske J, Parpieva N, Piubello A, Schwoebel V, Sikhondze W, Singla R, Souleymane MB, Trébucq A, Van Deun A, Viney K, Weyer K, Zhang BJ, Ahmad Khan F. Abidi S, et al. Among authors: maug akj. Eur Respir J. 2020 Mar 20;55(3):1901467. doi: 10.1183/13993003.01467-2019. Print 2020 Mar. Eur Respir J. 2020. PMID: 31862767
First-line tuberculosis treatment with double-dose rifampicin is well tolerated.
Maug AKJ, Hossain MA, Gumusboga M, Decroo T, Mulders W, Braet S, Buyze J, Arango D, Schurmans C, Herssens N, Demeulenaere T, Lynen L, de Jong BC, Van Deun A. Maug AKJ, et al. Int J Tuberc Lung Dis. 2020 May 1;24(5):499-505. doi: 10.5588/ijtld.19.0063. Int J Tuberc Lung Dis. 2020. PMID: 32398199 Clinical Trial.